Cerevel Therapeutics

Headquarters: Cambridge, Massachusetts, USA Ticker: CERE (NASDAQ) Founded: 2020 (spun off from Pfizer) Pipeline Focus: [Parkinson's Disease](/diseases/parkinsons-disease) disease, epilepsy, mood disorders

Overview

Headquarters: Cambridge, Massachusetts, USA Ticker: CERE (NASDAQ) Founded: 2020 (spun off from Pfizer) Pipeline Focus: [Parkinson's Disease](/diseases/parkinsons-disease) disease, epilepsy, mood disorders

Overview

Cerevel Therapeutics is a neuroscience-focused biotechnology company that was spun off from Pfizer in 2020 and went public in 2021. The company leverages its deep expertise in receptor selectivity and brain penetration to develop novel therapies for neurological and psychiatric disorders. Cerevel's lead program, CVN424, represents a novel approach to [Parkinson's Disease](/diseases/parkinsons-disease) disease treatment through selective dopamine D1/D5 receptor activation["@cvn"].

Cerevel's pipeline focuses on areas of high unmet need in neuroscience, including movement disorders, epilepsy, and mood disorders. The company's strategy combines internal discovery with strategic partnerships to advance its portfolio of novel molecules with differentiated pharmacology^2].

Parkinson's Disease Pipeline

CVN424

Mechanism: Selective dopamine D1 receptor partial agonist and D5 receptor agonist

Stage: Phase 2

Status: Clinical

CVN424 represents a novel approach to treating [Parkinson's Disease](/diseases/parkinsons-disease) disease motor symptoms through selective activation of dopamine D1 and D5 receptors. Unlike current dopamine agonists that broadly stimulate dopamine receptors, CVN424's selectivity profile may provide motor symptom relief with potentially reduced side effects including dyskinesia^3].

Clinical Development:

• Phase 1: Completed, demonstrating safety and target engagement
• Phase 2: Ongoing in [Parkinson's Disease](/diseases/parkinsons-disease) disease patients

• Selective D1/D5 agonist vs. non-selective dopamine agonists
• Potential for improved motor symptom control
• Reduced risk of dyskinesia development

CVN231

Mechanism: Undisclosed CNS target

Stage: Phase 1

Status: Clinical

CVN231 is Cerevel's second [Parkinson's Disease](/diseases/parkinsons-disease) disease program, currently in Phase 1 clinical trials. Additional details about the mechanism and target remain undisclosed^4].

[Multiple System Atrophy](/diseases/multiple-system-atrophy) Relevance

Cerevel's dopamine-focused pipeline has potential relevance to [Multiple System Atrophy](/diseases/multiple-system-atrophy):

• CVN424 (D1/D5 agonist): May provide symptomatic benefit for MSA-P variant patients with parkinsonism, as the selective D1/D5 mechanism could potentially address dopamine deficiency in striatonigral degeneration
• Motor symptom management: Cerevel's focus on movement disorders positions the company to potentially expand into MSA symptom management
• Partner ecosystem: Pfizer partnership provides resources for potential MSA program development

Additional Pipeline Programs

Epilepsy

| Program | Mechanism | Stage |
|---------|-----------|-------|
| CVL-231 | Kv7.2/7.3 potassium channel opener | Phase 2 |
| Undisclosed | Anti-seizure | Discovery |

Mood Disorders

| Program | Mechanism | Stage |
|---------|-----------|-------|
| CVL-231 | M4 muscarinic agonist | Phase 2 |
| CVL-561 | Undisclosed | Phase 1 |

Business Development

Pfizer Partnership

Cerevel was spun off from Pfizer with a strategic partnership that includes:

• Access to Pfizer's neuroscience pipeline compounds
• Research collaboration on novel targets
• Potential acquisition rights for Pfizer

Funding

• 2020: Raised $75M in Series A from Pfizer and Atlas Venture
• 2021: Raised $460M in Series B and IPO
• Current Market Cap: ~$2.5 billion (2024)

Scientific Approach

Cerevel's drug discovery platform focuses on:

Leadership

• CEO: Raymond K. (former Pfizer executive)
• CSO: Dr. John R. (neuroscience drug discovery expert)
• Board: Includes former FDA officials and biotech veterans

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-References

• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
• [Dopamine Receptors](/proteins/dopamine-receptors)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [MSA Treatment](/therapeutics/multiple-system-atrophy-msa-treatment)

References